June 30, 2025 Kigali, Rwanda and San Francisco, USA

Dr. Menghis Bairu, CEO, Co-Founder and President of Bio Usawa (BUI), together with Dr. Miriam Mutebi, internationally recognized surgical oncologist and President of AORTIC, are thrilled to announce the signing of a Memorandum of Understanding (MoU) to build a sustainable healthcare ecosystem for patients with cancer.

The partnership comes at a time when Africa’s population of 1.5 billion people remains largely underserved in terms of access to quality cancer care, skilled workforce, and effective therapies that are standard-of-care in higher income countries.

Through the newly formed collaboration, BUI and AORTIC will work together to change this equation by focusing on three key areas:

1. Building a translational research ecosystem focused on Women’s Health;

2. Capacity building through education and training, turning insights into tangible solutions in areas such as clinical research, regulatory strategy and pharmacovigilance;

3. Establishing a micro-grants program to support researchers at early stages in their careers.

The collaboration underscores a shared vision of delivering significantly better outcomes for oncology patients across Africa, and building capacity to strengthen healthcare resilience across the Continent.

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture and commercialize high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.